Since BRAF V600E mutations are currently considered an agnostic genetic alteration and seem to respond to BRAF inhibitors regardless of the primary tumor type, we recommend a BRAF inhibitor with or without a MEK inhibitor to patients with unresectable or metastatic BRAF mutant GISTs. This evidence concerns the gene MAP2K7 and neoplasm.